Raison d’être

According to the European Commission’s  Impact Assessment of Health Research Projects1 the original 15 member states had received 34 times more health research funding under FP7 than the 12 new members2.

The difference proves considerable imbalance and substantial  underfunding of research in the new member states.  Even  worse both participation rate  and funding of new member states of Eastern Europe have dropped since FP6.

The reason of existence of Cassovia Life Sciences  is to reverse  this regretful trend and correct  the imbalance through enabling its members to enhance their success  rate in project submissions and consortia building in Horizon 2020 and  other relevant framework programmes.


1. European Commission. Impact assessment of health research projects supported by DG Research and Innovation 2002–2010, http://ec.europa.eu/research/health/pdf/impact-assessment-of-health-research-projects-on-research-2002-2010_en.pdf

2. Galsworthy M. and McKee M.  Europe’s ‘Horizon 2020′ science funding programme: Horizon 2020′ science funding programme: How is it shaping up? J Health Serv Res Policy (2 May 2013, accessed 11 May 2013), link